We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+11.07%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.52B
AUM Growth
+$425M
Cap. Flow
+$155M
Cap. Flow %
2.81%
Top 10 Hldgs %
32.71%
Holding
141
New
18
Increased
27
Reduced
28
Closed
15

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$109M
2
UTHR icon
United Therapeutics
UTHR
+$89M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$87.1M
4
BAX icon
Baxter International
BAX
+$79M
5
CI icon
Cigna
CI
+$41.9M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$57.1M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$47M
3
BLU
BELLUS Health Inc.
BLU
+$36.8M
4
PGNY icon
Progyny
PGNY
+$33.3M
5
SYK icon
Stryker
SYK
+$27.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.75%
2 Industrials 1.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NXTC icon
101
NextCure
NXTC
$22.4M
$4.88M 0.09%
225,918
– –
ALKS icon
102
Alkermes
ALKS
$8.08B
$4.74M 0.09%
+151,400
New +$4.58M
NSPR icon
103
InspireMD
NSPR
$32.3M
$4.67M 0.08%
+1,860,405
New +$2.96M
VIGL
104
DELISTED
Vigil Neuroscience
VIGL
$4.22M 0.08%
448,891
– –
ARWR icon
105
Arrowhead Research
ARWR
$12.1B
$4.17M 0.08%
+117,000
New +$4.03M
APLM icon
106
Apollomics
APLM
$39.5M
$3.8M 0.07%
6,626
– –
BCAB icon
107
BioAtla
BCAB
$5.51M
$3.47M 0.06%
23,124
-54,096
-70% -$9.3M
CMMB
108
Chemomab Therapeutics
CMMB
$11.6M
$2.95M 0.05%
560,319
– –
SYBX
109
DELISTED
Synlogic
SYBX
$2.59M 0.05%
402,000
– –
RVNC
110
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.53M 0.05%
100,000
+50,000
+100% +$1.56M
EPIX
111
DELISTED
ESSA Pharma
EPIX
$2.49M 0.05%
921,940
-276,397
-23% -$810K
AFIB
112
DELISTED
Acutus Medical Inc
AFIB
$2.35M 0.04%
2,648,386
– –
ELEV
113
DELISTED
Elevation Oncology
ELEV
$2.28M 0.04%
+1,500,000
New +$3.96M
BOLT icon
114
Bolt Biotherapeutics
BOLT
$7.47M
$1.97M 0.04%
77,050
– –
TARA icon
115
Protara Therapeutics
TARA
$216M
$1.85M 0.03%
772,584
-20,974
-3% -$62.3K
PHGE icon
116
BiomX
PHGE
$1.95M
$1.64M 0.03%
23,966
+7,327
+44% +$425K
CALC icon
117
CalciMedica
CALC
$12M
$1.19M 0.02%
+297,380
New +$1.3M
TGTX icon
118
CALL
TG Therapeutics
TGTX
$8.1B
$1.14M 0.02%
+45,800
New +$1.18M
HRTX icon
119
Heron Therapeutics
HRTX
$92.3M
$931K 0.02%
802,700
– –
MRSN
120
CALL
DELISTED
Mersana Therapeutics
MRSN
$823K 0.01%
10,000
+1,572
+19% +$230K
OMIC
121
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$449K 0.01%
18,023
– –
HARP
122
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$441K 0.01%
62,122
– –
ALT icon
123
Altimmune
ALT
$580M
$353K 0.01%
100,000
+49,400
+98% +$222K
NKTR icon
124
CALL
Nektar Therapeutics
NKTR
$2.29B
$296K 0.01%
34,333
-2,000
-6% -$21.3K
ALT icon
125
CALL
Altimmune
ALT
$580M
– –
-100,000
Closed -$422K
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2023 Portfolio in Review

As of Q2 2023, OrbiMed held 141 positions worth $5.52B, up 8.3% from $5.09B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed's Q2 2023 filing shows 18 new, 27 increased, 28 reduced and 15 closed positions. Its largest new stake was ACELYRIN: 5,326,302 shares worth $111M. The largest sale was Bristol-Myers Squibb, an estimated $57.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Industrials.

  • OrbiMed's largest Q2 2023 buy was ACELYRIN: 5,326,302 shares worth $111M.
  • OrbiMed added most to Baxter International in Q2 2023, an estimated $79M increase.
  • OrbiMed's biggest Q2 2023 reduction was Bristol-Myers Squibb, cutting an estimated $57.1M.
  • OrbiMed fully exited Chinook Therapeutics, Inc. Common Stock in Q2 2023, selling an estimated $47M.
  • OrbiMed's ten largest holdings make up 33% of its $5.52B portfolio in Q2 2023.
  • OrbiMed opened 18 new positions and closed 15 in Q2 2023.
  • OrbiMed's portfolio value rose 8.3% quarter-over-quarter to $5.52B.

Based on OrbiMed's 13F filing for Q2 2023, filed 14 Aug 2023.